Ukraine: The Largest Fines Imposed By The Antimonopoly Committee Of Ukraine In 2018, And Its Enforcement Priorities

Last Updated: 4 April 2019
Article by Anastasia Usova and Nataliya Kovalyova
Most Read Contributor in Ukraine, September 2019

This overview is prepared based on the decisions issued by the Antimonopoly Committee of Ukraine (the "AMC") during the period from January to December 20181.

Merger control violations*

  • In 2018, almost a third of the decisions of the AMC to impose fines for merger control violations (92 of 25 decisions) were issued in relation to foreign-to-foreign concentrations. The largest and the lowest fines for failure to notify foreign-to-foreign concentrations were EUR 16,100 and EUR 5,360, respectively.
  • The AMC imposed a record-breaking fine of EUR 473,000 for failure to notify a concentration relating to the indirect acquisition by a sanctioned individual, an associate of former President of Ukraine Mr Viktor Yanukovych, in 2013 of some 80% of the shares of Brokbusinessbank – one of the largest Ukrainian banks.
  • To date, the second largest fine in the history of the Ukrainian merger control, of some EUR 110,000, was imposed by the AMC in 2016. In this case, the control was acquired over a company through the appointment of a member of the supervisory board who already held a director's position in another, unrelated, company. In its recent merger control reviews the AMC generally pays more attention to the facts of cross-directorship that result in the creation of control relations between different undertakings.
  • Overall, the authority now tends to impose higher fines, and the trend of stricter enforcement in merger control violations is expected to continue.

Please see pages 2-4 of the AMC Fines Review Table for more details

DOWNLOAD AMC Fines Review Table

Phase II cases and remedies

  • In 2018, the AMC received 532 merger control applications (compared with 666 in 2017) and considered 453 of these; 79 applications were rejected by the AMC as incomplete, or were withdrawn by the parties.
    In 2018, the AMC initiated Phase II in 253 cases, which related to 13 transactions structured in such a way that they required formal submission of several merger applications. Amongst 25 applications that were reviewed by the AMC in Phase II, the AMC granted approval in 19 cases while six others were closed without issuing a decision, including three involving parties subject to economic sanctions.
  • Interestingly, in 2018, all deals reviewed in Phase II received unconditional clearances. In 2017, amongst 11 Phase II decisions4 there were only three clearances with behavioural remedies, such as commitments not to engage in input foreclosure by unreasonably restricting access to relevant markets and reporting obligations regarding volumes of production, sale, export and import of goods; provision of copies of distribution agreements; and notification of price increases by more than 10%.
  • The number of Phase II reviews in 2017-2018 fell significantly as compared with previous periods; for instance, in 2016 the AMC cleared 54 concentrations as a result of Phase II, and in 2015 – 72. Such a decrease in the number of Phase II investigations is mainly due to amendments to the competition laws. Starting from mid-May 2016, the AMC may initiate Phase II only if a concentration may lead to monopolisation or a significant restriction of competition in the Ukrainian market or a significant part of it5.

Limitations on sanctioned companies and individuals

  • In 2018, the AMC blocked three transactions6 relating to the establishment by three independent founding parents (all foreign parties) of a joint venture outside of Ukraine as one of the founder's beneficiaries (a citizen of the Russian Federation) was subject to economic sanctions, introduced in connection with the Russian occupation of Crimea and the Donetsk region of Ukraine under the Law of Ukraine "On Sanctions".
  • Starting from December 2017, concentration shall not be cleared by the AMC if it is prohibited due to the Law of Ukraine "On Sanctions". As part of the merger control filing, each applicant should indicate if any individuals / legal entities related to it by control relations are included or not in the Ukrainian economic sanctions list. If yes, the respective applicant needs to justify that such legal entities / individuals and applicable economic sanctions have no impact on the particular transaction. Based on the review, the AMC then decides whether due to the sanctions the transaction should be blocked or not.

Antitrust investigations carried out by the AMC

  • In 2018, the AMC particularly focused on investigating the following markets:

    • supply and distribution of pharmaceutical products;
    • wholesale and retail sales of liquefied petroleum gas used as motor fuel;
    • wholesale of ethyl alcohol;
    • distribution of eco-labelled goods; and
    • distribution of food and beverages, in particular, alcoholic beverages and confectionery.
  • As a result of the investigations, the following largest fines were imposed in 2018**:

    • a EUR 1.3 million fine (in total)7 was applied to the five largest retailers (the "Retailers") of liquefied petroleum gas used as motor fuel ("LPG") for alleged parallel pricing behaviour in retail in August 2017. The AMC stated that such behaviour resulted in the unjustified overpricing of LPG and allowed the Retailers to benefit from the increased retail margins. According to the AMC, the Retailers also unreasonably increased their wholesale prices for LPG, thereby putting at a competitive disadvantage other smaller retailers which did not import LPG but purchased it from the Retailers for further resale in retail;
    • a EUR 1.04 million fine was applied to the state enterprise "Ukrspyrt" for abuse of its dominant position in the wholesale market for rectified ethyl alcohol, in particular, by setting different prices and discounts which did not correlate with purchase volumes of different buyers (e.g., buyers with larger purchase volume plans had higher purchase prices; or the same price applied to buyers with different purchase volumes). The AMC concluded that such discriminatory pricing without any objectively justified reasons could put some of the buyers at a competitive disadvantage;
    • after six years of investigation, the AMC imposed a fine on Roche Ukraine LLC (EUR 290,000) and its three largest Ukrainian distributors, namely BaDM LLC (EUR 170,000), Business Centre Pharmacy LLC (EUR 100,000) and Alba Ukraine PrJSC (EUR 10,000), for anticompetitive concerted practices which allegedly led to the overpricing of pharmaceuticals sold in public procurement tenders (the "Tenders") during 2012-20168. According to the AMC, bonuses granted to the distributors ex post in the form of non-repayable financial aid after winning of the relevant bid, and calculated as a percentage from the respective Tender sales, were not reflected in the Tender prices. According to the AMC, since the bonuses were not passed on to end-consumers, they only served as a source of additional profit for the distributors, and led to the unjustified overpricing of Roche's pharmaceuticals sold in Tenders as compared with the retail prices for the same medicines sold in pharmacies.

      This is the fourth fine imposed in a series of pharmaceutical investigations within the same probe dating back to 2012. In 2017, a much higher fine was imposed on Sanofi Aventis Ukraine LLC (EUR 2 million) and its two largest distributors: Optima-Pharm LLC (EUR 1.2 million) and BaDM LLC (EUR 860,000) in relation to their distribution practices. All of the respondents have successfully reversed the AMC decision in court as being based on insufficient evidence that the rebate system introduced by Sanofi had anticompetitive effects in the form of market foreclosure for cheaper generic substitutes of Sanofi's products and overpricing of Sanofi pharmaceuticals sold at public procurement tenders.

      Interestingly, in January 2019, in another case relating to the same probe, the AMC issued recommendations to Bayer LLC and its three Ukrainian distributors to "stop practices containing signs of violation of the competition law by bringing their contractual arrangements in compliance with the competition law". According to the AMC, the main difference between this case and all previous pharmaceutical cases is "absence of appreciable effect in the form of unjustified price increase for pharmaceuticals sold at public procurement tenders".

      To enhance legal certainty, in February 2019, the AMC issued guidelines on vertical restraints relating to the supply and promotion of pharmaceuticals. The guidelines are aimed at providing practical guidance on the assessment of vertical agreements in the pharmaceutical sector and clarifying which distribution practices (e.g., particular sales promotion activities, conditions for provision of discounts, rebates and bonuses, pricing conduct, reporting obligations, etc.) may have anticompetitive effects.


1 According to the Annual Report of the AMC for 2018, as well as publicly available information, based on the decisions and information notices published on the AMC's web-site.

2 According to our internal calculations, based on the decisions published on the AMC's web-site.

3 According to our internal calculations, based on the decisions and information notices published on the AMC's web-site.

4 According to the Annual Report of the AMC for 2017.

5 Before mid-May 2016, the AMC could initiate Phase II if there was a need to conduct an "in-depth comprehensive market study or analysis".

6 According to the Annual Report of the AMC for 2018.

7 In 2016, the AMC imposed almost a fivefold fine of EUR 7.3 million on seven petrol retailers for alleged parallel pricing behaviour in the market of retail sale of petrol and diesel. As of 18 March 2019, four retailers are still challenging the AMC decision in court. The claims of the rest of the retailers were dismissed and two of them already paid their fines.

8 As of 22 March 2019, Roche Ukraine LLC, BaDM LLC and Business Centre Pharmacy LLC are challenging the AMC decision in court.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions